AR079712A1 - Composiciones inmunogenicas; kit y vacuna - Google Patents

Composiciones inmunogenicas; kit y vacuna

Info

Publication number
AR079712A1
AR079712A1 ARP100104897A ARP100104897A AR079712A1 AR 079712 A1 AR079712 A1 AR 079712A1 AR P100104897 A ARP100104897 A AR P100104897A AR P100104897 A ARP100104897 A AR P100104897A AR 079712 A1 AR079712 A1 AR 079712A1
Authority
AR
Argentina
Prior art keywords
composition
pneumoniae
isolated
immunogenic
polypeptide
Prior art date
Application number
ARP100104897A
Other languages
English (en)
Spanish (es)
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Publication of AR079712A1 publication Critical patent/AR079712A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP100104897A 2009-12-22 2010-12-22 Composiciones inmunogenicas; kit y vacuna AR079712A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28923609P 2009-12-22 2009-12-22
US32566010P 2010-04-19 2010-04-19

Publications (1)

Publication Number Publication Date
AR079712A1 true AR079712A1 (es) 2012-02-15

Family

ID=44194860

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104897A AR079712A1 (es) 2009-12-22 2010-12-22 Composiciones inmunogenicas; kit y vacuna

Country Status (12)

Country Link
US (1) US20130183350A1 (cg-RX-API-DMAC10.html)
EP (1) EP2515938A4 (cg-RX-API-DMAC10.html)
JP (2) JP5894083B2 (cg-RX-API-DMAC10.html)
KR (1) KR20120107121A (cg-RX-API-DMAC10.html)
CN (1) CN102802664B (cg-RX-API-DMAC10.html)
AR (1) AR079712A1 (cg-RX-API-DMAC10.html)
AU (1) AU2010335970B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012018343A2 (cg-RX-API-DMAC10.html)
CA (1) CA2783955A1 (cg-RX-API-DMAC10.html)
IL (2) IL220576B (cg-RX-API-DMAC10.html)
WO (1) WO2011075823A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201204628B (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075822A1 (en) 2009-12-22 2011-06-30 Sanofi Pasteur Limited Immunogenic compositions and related methods
AU2011336366B2 (en) * 2010-12-03 2016-05-12 Sanofi Pasteur Limited Composition for immunization against Streptococcus pneumoniae
KR20140033127A (ko) 2011-05-17 2014-03-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애에 대한 백신
WO2014060385A1 (en) * 2012-10-17 2014-04-24 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
CA2894903A1 (en) * 2012-12-14 2014-06-19 Sanofi Pasteur, Ltd. Methods for assessing immunogenicity
CA2941826A1 (en) * 2014-03-10 2015-09-17 Sanofi Pasteur Limited Immunogenic compositions
KR101688960B1 (ko) * 2014-06-11 2016-12-23 전남대학교산학협력단 스쿠티카충 백신 조성물
CN107206066A (zh) * 2015-01-27 2017-09-26 3M创新有限公司 用于微针疫苗贴剂的含明矾的涂层制剂
US11173197B2 (en) 2015-07-07 2021-11-16 Bluewillow Biologics, Inc. Methods and compositions for nanoemulsion vaccine formulations
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
WO2023034932A1 (en) * 2021-09-02 2023-03-09 Vaxcyte, Inc. Stabilization of adjuvanted vaccine compositions and their use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3237842B2 (ja) * 1988-12-16 2001-12-10 オランダ国 ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
CA2355364C (en) * 1998-12-21 2014-03-18 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
DK1861120T3 (en) * 2005-03-23 2016-07-25 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US20110002962A1 (en) 2006-08-17 2011-01-06 The Uab Research Foundation Immunogenic PcpA Polypeptides and Uses Thereof
CA2694466A1 (en) 2007-07-23 2009-01-29 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
CN101952728B (zh) * 2008-02-01 2016-05-11 圣诺菲·帕斯图尔有限公司 用于诊断肺炎链球菌的试验
CN106008679A (zh) * 2008-12-24 2016-10-12 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 修饰的肺炎链球菌溶血素(ply)多肽

Also Published As

Publication number Publication date
BR112012018343A2 (pt) 2017-06-27
AU2010335970A1 (en) 2012-07-05
JP5894083B2 (ja) 2016-03-23
KR20120107121A (ko) 2012-09-28
ZA201204628B (en) 2013-02-27
EP2515938A4 (en) 2013-08-28
AU2010335970B2 (en) 2016-11-03
JP2013515015A (ja) 2013-05-02
IL242592A (en) 2017-10-31
CN102802664A (zh) 2012-11-28
IL220576B (en) 2018-03-29
JP2016104776A (ja) 2016-06-09
WO2011075823A1 (en) 2011-06-30
US20130183350A1 (en) 2013-07-18
CN102802664B (zh) 2017-04-05
EP2515938A1 (en) 2012-10-31
CA2783955A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
AR054822A1 (es) Emulsion inmuno adyuvante
SI2280721T1 (en) Indoleamine 2, 3-dioxygenase based immunotherapy
PE20250020A1 (es) Composicion inmunogenica contra la influenza
PE20161560A1 (es) Vacuna de pcsk9
PE20080428A1 (es) Vacunas para la malaria
MX2018007860A (es) Vacunas recombinantes contra el zika.
PE20121685A1 (es) Antigeno ndv recombinante y usos del mismo
CL2016002513A1 (es) Método para preparar amg 416
MX2017014127A (es) Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos.
MX359954B (es) Ácido nucleico que comprende o codifica para un asa troncal de histona y una secuencia poly (a) o una señal de poliadenilación para aumentar la expresión de un antígeno patogénico codificado.
MX2017011796A (es) Lo nuevo complejo que comprende un peptido de penetracion celular, una molecula cargo y un agonista peptidico de tlr.
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
PE20140986A1 (es) Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae
AR079706A1 (es) Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso
MX2019005137A (es) Vacuna contra parvovirus porcino.
AR109538A1 (es) Vacuna contra la gripe porcina
AR071741A1 (es) Vacunas contra la malaria
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
AR099960A1 (es) Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria
MX2021004859A (es) Vacuna de ibv h52 con proteina espicular heterologa.
AR088907A1 (es) Vacuna

Legal Events

Date Code Title Description
FB Suspension of granting procedure